VIDEO: Cell therapy demonstrates positive phase 3 results for macular telangiectasia
Click Here to Manage Email Alerts
SEATTLE — In this Healio Video Perspective from the ASRS meeting, Emily Y. Chew, MD, discusses the results of two phase 3 trials investigating NT-501 for the treatment of macular telangiectasia type 2.
NT-501 (revakinagene taroretcel, Neurotech Pharmaceuticals) is an encapsulated cell therapy that is implanted into the eye and designed to deliver ciliary neurotrophic factor to slow disease progression.
“Phase 1, 2 and 3 showed it to be very safe,” Chew said. “Phase 2 and phase 3 mirrored each other in that there was a reduction in the risk of [ellipsoid zone] loss for patients with macular telangiectasia. This is a disease that we have never had treatment for, so this indeed is a first, and it is using an encapsulated cell therapy, which again, is also a first.”
Collapse
Chew E. Phase 3 randomized studies of efficacy and safety of revakinagene taroretcel producing ciliary neurotrophic factor (CNTF) in macular telangiectasia type 2. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Read more about
Click Here to Manage Email Alerts